Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Xiao Wan from Professor Eric O’Neill’s group for her success in obtaining an NC3Rs Training Fellowship for ‘Developing human organotypic perfused bioreactors for physiologically reproducible therapeutic compound screening of a tumour microenvironment’.

Xiao's research at the CRUK/MRC Oxford Institute for Radiation Oncology in the Department of Oncology focuses on developing bioreactors that more accurately recapitulate the tumour microenvironment, including the interplay of tumour and stromal cells, than current in vitro systems, by including perfusion by blood vessels.

In 2017, the National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) announced seven new fellowships, a commitment of nearly £1.2 million, to support talented early career scientists in the discovery and development of new technologies and approaches to replace, reduce and refine the use of animals in scientific research. The NC3Rs provides two type of fellowships awards: Training Fellowships for researchers with less than three years postdoctoral experience and the intermediate career stage David Sainsbury Fellowships for researchers with two to six years of postdoctoral experience.

Using the funding from the Training Fellowship, Xiao hopes to develop highly interdisciplinary tools for creating artificial tissue in perfusion culture to replicate physiological and pathological processes with less chemical fluctuation and biological stress.

Xiao commented: "The outcome will benefit the oncology research communities, including researchers in Oxford as well as my collaborators in China, by enabling them to test their therapeutics in a better-defined tissue microenvironment compared with petri-dish methods. The techniques optimised by this project will have the potential to replace and reduce the use of animals in the preclinical evaulation of therapeutics, especially those targeting at tissue microenvironment, such as the epigenetic events in cancer development."

Further information about Xiao's project can be found on the NC3Rs website.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.